替格瑞洛与氯吡格雷对老年冠心病患者HCY、hs-CRP、IL-6水平的影响

Effects of ticagrelor and clopidogrel on the levels of HCY,hs-CRP,IL-6 in elderly patients with coronary heart disease

目的探究替格瑞洛与氯吡格雷对老年冠心病患者HCY、hs-CRP、IL-6水平的影响。方法选取本院2018年11月至2019年12月收治的62例老年冠心病患者,根据治疗药物的不同,分为替格瑞洛组和氯吡格雷组,每组31例。比较两组患者HCY、hs-CRP、IL-6水平及不良反应发生率。结果治疗后,替格瑞洛组HCY、hs-CRP、IL-6水平均低于氯吡格雷组(P<0.05);替格瑞洛组不良反应发生率低于氯吡格雷组(P<0.05)。结论替格瑞洛可有效改善老年冠心病患者HCY、hs-CRP、IL-6水平,且不良反应发生率低,安全性较高,可作为治疗冠心病的首选药物。

Objective To explore the effects of ticagrelor and clopidogrel on HCY,hs-CRP and IL-6 levels in elderly patients with coronary heart disease.Methods 62 elderly patients with coronary heart disease admitted to our hospital from November 2018 to December 2019 were selected and divided into ticagrelor group and clopidogrel group according to different treatment drugs,with 31 cases in each group.The levels of HCY,hs-CRP,IL 6 and the incidence of adverse reactions were compared between two groups.Results After treatment,the levels of HCY,hs-CRP and IL-6 in ticagrelor group were lower than those in clopidogrel group(P<0.05).The incidence of adverse reactions in ticagrelor group was lower than that in clopidogrel group(P<0.05).Conclusion Ticagrelor can effectively improve the levels of HCY,hs-CRP and IL-6 in elderly patients with coronary heart disease,with low incidence of adverse reactions and high safety,and can be used as the first choice for the treatment of coronary heart disease.